However, all the RCTs with anti-CGRP mAbs in migraine patients with prior therapeutic failures (Liberty, erenumab; Conquer, galcanezumab; Focus, fremanezumab; Deliver, eptinezumab) based their primary efficacy outcome upon at least 50% response rate [19–22]. Here, CALCA is linked to migraine disorder.